PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells

Blood Cancer J. 2016 Jan 8;6(1):e377. doi: 10.1038/bcj.2015.109.

Authors

E Glodkowska-Mrowka¹, A Manda-Handzlik^{1

2}, A Stelmaszczyk-Emmel¹, I Seferynska³, T Stoklosa⁴, J Przybylski⁵, P Mrowka⁵

Affiliations

¹ Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Warsaw, Poland.
² Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland.
³ Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
⁴ Department of Immunology, Medical University of Warsaw, Warsaw, Poland.
⁵ Department of Biophysics and Human Physiology, Medical University of Warsaw, Warsaw, Poland.

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Benzamides / administration & dosage*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
Neoplastic Stem Cells / drug effects*
PPAR gamma / agonists*
Piperazines / administration & dosage*
Pyrimidines / administration & dosage*
Thiazolidinediones / administration & dosage*

Substances

Benzamides
PPAR gamma
Piperazines
Pyrimidines
Thiazolidinediones